PYC Therapeutics

20 October 2023

PYC PRESENTING ON PYC-001 PROGRAM AT OLIGONUCLEOTIDE THERAPEUTIC SOCIETY 2023 MEETING

PERTH, Australia and SAN FRANCISCO, California – 20 October 2023

PYC Therapeutics (ASX:PYC) today announced an upcoming poster presentation at the Oligonucleotide Therapeutics Society (OTS) 2023 Annual Meeting taking place in Barcelona, Spain 22-25 October 2023. The poster presentation highlights preclinical data from PYC's second drug development program addressing a blinding eye disease of childhood called Autosomal Dominant Optic Atrophy (ADOA). The data supports the progression of PYC's drug candidate (known as PYC-001) into human studies as a potential treatment option for patients with ADOA that addresses the underlying cause of the disease.

Key Highlights:

- PYC has demonstrated that its RNA therapy for ADOA is both safe and effective in Non-Human Primates[1] following a single dose of the drug
- PYC's RNA therapy for ADOA is capable of increasing expression of the missing protein that underlies disease causation in models derived from patients with ADOA[1]
- Increasing expression of the missing protein in ADOA patient-derived models is associated with rescue of the functional deficits observed in these models suggesting that PYC's drug candidate can arrest progression of the disease
- PYC is currently progressing this drug candidate into human trials expected to begin next year

The poster presentation can be accessed on demand throughout the meeting by conference attendees on the OTS 2023 Annual Meeting website, or on PYC's website in the Posters and Publications section of the Pipeline page.

About PYC Therapeutics

PYC Therapeutics (ASX: PYC) is a clinical-stage biotechnology company creating a new generation of RNA therapies to change the lives of patients with genetic diseases. The Company utilises its proprietary drug delivery platform to enhance the potency of precision medicines within the rapidly growing and commercially proven RNA therapeutic class.

[1]Refer to ASX announcement 4 October 2023

PYC's drug development programs target monogenic diseases – **the indications with the highest likelihood of success in clinical development.**[2]

The Company was the first to progress a drug candidate for a blinding eye disease of childhood into human trials and is now progressing multiple 'fast-follower' programs into the clinic. For more information, visit pyctx.com, or follow us on LinkedIn and Twitter.

Forward looking statements

Any forward-looking statements in this ASX announcement have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside the Company's control. Important factors that could cause actual results to differ materially from assumptions or expectations expressed or implied in this ASX announcement include known and unknown risks. Because actual results could differ materially to assumptions made and the Company's current intentions, plans, expectations and beliefs about the future, you are urged to view all forward-looking statements contained in this ASX announcement with caution. The Company undertakes no obligation to publicly update any forward-looking statement whether as a result of new information, future events or otherwise.

This ASX announcement should not be relied on as a recommendation or forecast by the Company. Nothing in this ASX announcement should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction.

This ASX announcement was approved and authorised for release by the CEO of PYC Therapeutics Limited

CONTACTS:

INVESTORS and MEDIA
info@pyctx.com

[2] Advancing Human Genetics Research and Drug Discovery through Exome Sequencing of the UK Biobank https://doi.org/10.1101/2020.11.02.20222232